08J

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

US and EU compete on regulatory vigor; former chiefs seek elevation of status for FDA

This week, Phispers reports on Sanofi and Boehringer Ingelheim’s asset swap, a possible cure f